Advancing into a new era of precision medicine in early diagnosis and treatment of Alzheimer′s disease
10.3760/cma.j.cn113694-20240420-00285
- VernacularTitle:阿尔茨海默病早期诊疗迈入“精准医学”新时代
- Author:
Jintai YU
1
;
Xiaochun CHEN
Author Information
1. 复旦大学附属华山医院神经内科，上海 200040
- Keywords:
Alzheimer disease;
Mild cognitive impairment;
Biological markers;
Early diagnosis;
Early treatment
- From:
Chinese Journal of Neurology
2024;57(7):691-697
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, precision medicine has made significant progress in the early diagnosis and treatment of Alzheimer′s disease (AD), bringing revolutionary changes to traditional models. In response to these innovative developments, the Chinese Society of Dementia and Cognitive Impairment, starting from the needs of China′s healthcare system and patients, has formulated and released the "Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to Alzheimer′s disease 2024". This consensus establishes a systematic and comprehensive diagnostic and therapeutic framework, which not only provides practical guidelines for implementation but also lays a solid foundation for the new stage of precise prevention and treatment of AD. Based on this, in-depth discussions and comments were conducted on AD′s biomarkers, clinical diagnostic criteria, disease staging, and early intervention strategies, aiming to assist clinical and research professionals in constructing a comprehensive AD precision medicine system and to emphasize the importance of early precision recognition and management of the disease, thus advancing early diagnostic and therapeutic efforts for AD into a new era of precision medicine.
